Early opportunity

Preliminary data from ongoing studies of lead candidate Hu5F9-G4 enabled Forty Seven Inc. to raise a $75 million series B round sooner than expected.

The new funds will allow Forty Seven to launch and complete three additional studies of Hu5F9-G4 in combination with undisclosed checkpoint inhibitors, and thus evaluate a broader range of combination regimens before deciding on a registrational trial strategy...